Purpose: To review the literature to define the efficacy of intravenous (IV) amiodarone in the treatment of atrial fibrillation in the nonsurgical patient. Method: A MEDLINE search was conducted using the key words “intravenous amiodarone” and “atrial fibrillation.” All trials evaluating the use of intravenous amiodarone in the surgical setting were excluded. Results: Twenty articles were identified, which were divided into acute and chronic atrial fibrillation. Within the acute setting, IV amiodarone was used alone, compared to a placebo-control, or compared to active drug regimens. In the trials without a control group, it was difficult to determine how much of the effect was due to spontaneous conversion. When compared to placebo, IV amiodarone offered a 61% to 92% conversion at 24 hours. Compared to active drug therapy, there was a trend to increased efficacy at 24 hours. However, amiodarone was no more effective for the conversion of atrial fibrillation than alternative therapies. In the case of chronic atrial fibrillation, intravenous amiodarone had no benefit. The incidence of thrombophlebitis, bradycardia, and hypotension was quite high, reported to be around 15% to 30% in many of the trials. Conclusion: The use of intravenous amiodarone should not be recommended as the first line agent for the conversion of atrial fibrillation.
Fuster V , Ryden LE, Asinger RW, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to develop guidelines for the management of patients with atrial fibrillation). J Am Coll Cardiol. 2001;38:i-lxx.
2.
Ostranderld JR , Brandt RL, Kjelsberg MO, et al. Electrocardiographic finding among the adult population of a total natural community, Tecumeseh, Michigan. Circulation. 1965;31:888-898.
3.
Psaty BM , Manolio TA, Kuller LH, et al. Incidence of and risk factors for atrial fibrillation in older adults. Circulation. 1997;96:2455-2461.
4.
Podrid PJ . Amiodarone: reevaluation of an old drug. Ann Intern Med. 1995;122:689-700.
5.
Singh BN , Venkatesh N, Nademanee K, et al. The historical development, cellular electrophysiology, and pharmacology of amiodarone. Prog Cardiovasc Dis. 1989:31:249-280.
6.
Hohnloser SH , Zabel M, Zehender M, et al. Efficacy of intravenously administered amiodarone for short-term control of serious arrhythmias. J Cardiovas Pharmacol. 1992;20:S63-S69.
7.
Naccarelli GV , Jalal S.Intravenous amiodarone: another option in the acute management of sustained ventricular tachyarrhythmias [editorial]. Circulation. 1995;92:3154-3155.
8.
Wellen HJ , Brugada P, Abdollah H.A comparison of the electrophysiologic effects of intravenous and oral amiodarone in the same patient. Circulation. 1984;69:120-124.
9.
Ikeda N , Nademanee K, Kannan R, Singh BN. Electrophysiologic effects of amiodarone: experimental and clinical observation relative to serum and tissue drug concentrations. Am Heart J. 1984;108:890-898.
10.
Yabek SM , Kato R, Singh BN. Effects of amiodarone and its metabolite, desmethylamiodarone, on the electrophysiologic properties of isolated cardiac muscle. J Cardiovasc Pharmacol. 1986;8:197-207.
11.
Desai AD , Chun S, Sung RJ. The role of intravenous amiodarone in the management of cardiac arrhythmias. Ann Intern Med. 1997;127:294-303.
12.
Faniel R , Schoenfeld R.Efficacy of IV amiodarone in converting rapid atrial fibrillation and flutter to sinus rhythm in intensive care patients. Eur Heart J. 1983;4:180-185.
13.
Strasberg B , Arditti A, Sclarovsky S, et al. Efficacy of intravenous amiodarone in the management of paroxysmal or new atrial fibrillation with fast ventricular response. Int J Cardiol. 1985;7:47-55.
14.
Vietti-Ramus G , Veglio F, Marchisio U, et al. Efficacy and safety of short intravenous amiodarone in supraventricular tachyarrythmias. Int J Cardiol. 1992;35:77-85.
15.
Cybulski J , Kulakowski P, Makowka E, et al. Intravenous amiodarone is safe and seems to be effective in termination of paroxysmal supraventricular tachyarrhythmias. Clin Cardiol. 1996;19:563-566.
16.
Kreiss Y , Sidi Y, Gur H.Efficacy and safety of intravenous amiodarone in recent-onset atrial fibrillation: experience in patients admitted to a general internal medicine department. Postgrad Med J. 1999;75:278-281.
17.
Galve E , Rius T, Ballester R, et al. Intravenous amiodarone in treatment of recent-onset atrial fibrillation: results of a randomized, controlled study. J Am Coll Cardiol. 1996;27:1079-1082.
18.
Cotter G , Blatt A, Kaluski E, et al. Conversion of recent onset paroxysmal atrial fibrillation to normal sinus rhythm: the effect of no treatment and high-dose amiodarone. Eur Heart J. 1999;20:1833-1842.
19.
Vardas PE , Kochiadakis GE, Igoumenidis NE, et al. Amiodarone as a first-choice drug for restoring sinus rhythm in patients with atrial fibrillation. Chest. 2000;117:1538-1545.
20.
Cowan JC , Gardiner P, Reid DS, et al. A comparison of amiodarone and digoxin in the treatment of atrial fibrillation complicating suspected AMI. J Cardiovasc Pharmacol. 1986;8:252-256.
21.
Noc M , Stajer D, Horvat M.Intravenous amiodarone versus verapamil for acute conversion of paroxysmal atrial fibrillation to sinus rhythm. Am J Cardiol. 1990;65:679-680.
22.
Pilati G , Lenzi T, Trisolino G, et al. Amiodarone versus quinidine for conversion of recent-onset atrial fibrillation to sinus rhythm. Curr Ther Res. 1991;49:140-146.
23.
Capucci A , Lenzi T, Boriani G, et al. Effectiveness of loading oral flecainide for converting recent-onset atrial fibrillation to sinus rhythm in patients without organic heart disease or with only systemic hypertension. Am J Cardiol. 1992;70:69-72.
24.
Horner SM . A comparison of cardioversion of atrial fibrillation using oral amiodarone, intravenous amiodarone, and DC cardio-version. Acta Cardiol. 1992;47:473-480.
25.
Chapman MJ , Moran JL, O’Fathartaigh MS, et al. Management of atrial tachyarrhythmias in the critically ill: a comparison of intravenous procainamide and amiodarone. Intensive Care Med. 1993;19:48-52.
26.
Andrivet P , Boubakri E, Dove PJ, et al. A clinical study of amiodarone as a single oral dose in patients with recent-onset atrial tachyarrhythmia. Eur Heart J. 1994;15:1396-1402.
27.
Hou ZY , Chang MS, Chen CY, et al. Acute treatment of recent-onset atrial fibrillation and flutter with a tailored dosing regimen of intravenous amiodarone. Eur Heart J. 1995;16:521-528.
28.
Boriani G , Biffi M, Capucci A, et al. Conversion of recent-onset atrial fibrillation to sinus rhythm: effects of different drug protocols. Pacing and Clinical Electrophysiology. 1998;21:2470-2474.
29.
Kontoyannis DA , Anastasiou-Nana MI, Kontoyannis S, et al. Intravenous amiodarone decreases the duration of atrial fibrillation associated with AMI. Cardiovasc Drugs Ther. 2001;15:155-160.
30.
Kerin NZ , Faitel K, Naini M.The efficacy of intravenous amiodarone for the conversion of chronic atrial fibrillation. Arch Intern Med. 1996;156:49-53.
31.
Kochiadakis GE , Igoumenidis NE, Solomou MC, et al. Efficacy of amiodarone for the termination of persistent atrial fibrillation. Am J Cardiol. 1999;83:58-61.
